Kerri A Johannson

List of Publications by Year
in descending order

Version: 2024-02-01

102 papers	3,565 citations	172207 29 h-index	149479 56 g-index
104 all docs	104 docs citations	104 times ranked	2536 citing authors

#	Article	IF	Citations
1	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	2.5	508
2	Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. European Respiratory Journal, 2014, 43, 1124-1131.	3.1	217
3	Palliative care in interstitial lung disease: living well. Lancet Respiratory Medicine,the, 2017, 5, 968-980.	5.2	185
4	Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest, 2017, 151, 619-625.	0.4	177
5	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	2.5	174
6	Diagnostic Yield and Complications of Transbronchial Lung Cryobiopsy for Interstitial Lung Disease: A Systematic Review and Meta-analysis. Annals of the American Thoracic Society, 2016, 13, 1828-1838.	1.5	158
7	Pathologic Findings and Prognosis in a LargeÂProspective Cohort of Chronic Hypersensitivity Pneumonitis. Chest, 2017, 152, 502-509.	0.4	131
8	Diagnosis and Evaluation of Hypersensitivity Pneumonitis. Chest, 2021, 160, e97-e156.	0.4	104
9	The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax, 2017, 72, 424-429.	2.7	103
10	Air Pollution Exposure. Chest, 2015, 147, 1161-1167.	0.4	85
11	YouTube Videos as a Source of Misinformation on Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2019, 16, 572-579.	1.5	82
12	Air Pollution Exposure Is Associated With Lower Lung Function, but Not Changes in Lung Function, in Patients With Idiopathic Pulmonary Fibrosis. Chest, 2018, 154, 119-125.	0.4	76
13	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international caseâ€“cohort study. European Respiratory Journal, 2017, 50, 1700936.	3.1	75
14	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respiratory Medicine,the, 2017, 5, 591-598.	5.2	71
15	A diagnostic model for chronic hypersensitivity pneumonitis. Thorax, 2016, 71, 951-954.	2.7	70
16	Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1602406.	3.1	66
17	Exertional hypoxemia is more severe in fibrotic interstitial lung disease than in COPD. Respirology, 2018, 23, 392-398.	1.3	63
18	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1146-1153.	2.5	60

#	Article	IF	Citations
19	Bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: a systematic review and meta-analysis. European Respiratory Journal, 2020, 56, 2000206.	3.1	58
20	Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic. Chest, 2020, 158, 1069-1078.	0.4	57
21	Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. European Respiratory Journal, 2022, 60, 2102571.	3.1	57
22	Treatment of fibrotic interstitial lung disease: current approaches and future directions. Lancet, The, 2021, 398, 1450-1460.	6.3	47
23	The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry. Canadian Respiratory Journal, 2016, 2016, 1-7.	0.8	45
24	Exposure Assessment Tools for Hypersensitivity Pneumonitis. An Official American Thoracic Society Workshop Report. Annals of the American Thoracic Society, 2020, 17, 1501-1509.	1.5	45
25	Acute exacerbation of idiopathic pulmonary fibrosis: a proposal. Current Respiratory Care Reports, 2013, 2, 233-240.	0.6	37
26	High Oxygen Delivery to Preserve Exercise Capacity in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib. Methodology of the HOPE-IPF Study. Annals of the American Thoracic Society, 2016, 13, 1640-1647.	1.5	37
27	Oxygen in patients with fibrotic interstitial lung disease: an international Delphi survey. European Respiratory Journal, 2019, 54, 1900421.	3.1	33
28	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.4	33
29	Supplemental Oxygen in Interstitial Lung Disease: An Art in Need of Science. Annals of the American Thoracic Society, 2017, 14, 1373-1377.	1.5	30
30	Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis. Thorax, 2020, 75, 407-412.	2.7	30
31	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. European Respiratory Journal, 2021, 58, 2001518.	3.1	30
32	Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. Respiratory Research, 2020, 21, 12.	1.4	29
33	Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease. Thorax, 2021, 76, 37-43.	2.7	28
34	Mobile Health Monitoring in Patients with Idiopathic Pulmonary Fibrosis. Annals of the American Thoracic Society, 2019, 16, 1327-1329.	1.5	26
35	Neighborhood-Level Disadvantage Impacts on Patients with Fibrotic Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 459-467.	2.5	25
36	Association of BMI and Change in Weight With Mortality in Patients With Fibrotic Interstitial Lung Disease. Chest, 2022, 161, 1320-1329.	0.4	25

#	Article	IF	Citations
37	Validity of administrative data for identification of obstructive sleep apnea. Journal of Sleep Research, 2017, 26, 132-138.	1.7	22
38	Survival after inpatient or outpatient pulmonary rehabilitation in patients with fibrotic interstitial lung disease: a multicentre retrospective cohort study. Thorax, 2022, 77, 589-595.	2.7	21
39	Incidence and Prognostic Significance of Hypoxemia in Fibrotic Interstitial Lung Disease. Chest, 2021, 160, 994-1005.	0.4	20
40	Exposures and associations with clinical phenotypes in hypersensitivity pneumonitis: A scoping review. Respiratory Medicine, 2021, 184, 106444.	1.3	19
41	Sex and gender in interstitial lung diseases. European Respiratory Review, 2021, 30, 210105.	3.0	19
42	Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis. Chest, 2022, 162, 614-629.	0.4	19
43	A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease. Respiratory Research, 2020, 21, 322.	1.4	18
44	Update in Interstitial Lung Disease 2019. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 500-507.	2.5	17
45	Air Pollution and Interstitial Lung Diseases: Defining Epigenomic Effects. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1217-1224.	2.5	16
46	Travel Distance to Subspecialty Clinic and Outcomes in Patients with Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 20-27.	1.5	16
47	Evaluation of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 133-141.	0.2	15
48	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	2.5	15
49	Costs of Workplace Productivity Loss in Patients With Fibrotic Interstitial Lung Disease. Chest, 2019, 156, 887-895.	0.4	14
50	Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. ERJ Open Research, 2021, 7, 00405-2021.	1.1	14
51	Relative environmental and social disadvantage in patients with idiopathic pulmonary fibrosis. Thorax, 2022, 77, 1237-1242.	2.7	14
52	Making an Accurate Diagnosis of Chronic Hypersensitivity Pneumonitis. Canadian Respiratory Journal, 2014, 21, 370-372.	0.8	13
53	Air pollution exposure and IPF: prevention when there is no cure. Thorax, 2018, 73, 103-104.	2.7	12
54	Inhalational exposures in patients with fibrotic interstitial lung disease: Presentation, pulmonary function and survival in the <scp>Canadian Registry</scp> for <scp>Pulmonary Fibrosis</scp>. Respirology, 2022, 27, 635-644.	1.3	12

#	Article	IF	Citations
55	Genetic testing in interstitial lung disease: An international survey. Respirology, 0, , .	1.3	10
56	Comparing the Performance of Two Recommended Criteria for Establishing a Diagnosis for Hypersensitivity Pneumonitis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 865-868.	2.5	9
57	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT. Lancet Respiratory Medicine,the, 2014, 2, e5.	5.2	8
58	Models of disease behavior in idiopathic pulmonary fibrosis. BMC Medicine, 2015, 13, 165.	2.3	8
59	Comprehensive management of fibrotic interstitial lung diseases: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 234-243.	0.2	8
60	Autoantibody status is not associated with change in lung function or survival in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2019, 153, 85-90.	1.3	7
61	Oxygen for interstitial lung diseases. Current Opinion in Pulmonary Medicine, 2020, 26, 464-469.	1.2	7
62	Remote Monitoring in Idiopathic Pulmonary Fibrosis: Home Is Where the Bluetooth-enabled Spirometer Is. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 316-317.	2.5	7
63	Social Media Content of Idiopathic Pulmonary Fibrosis Groups and Pages on Facebook: Cross-sectional Analysis. JMIR Public Health and Surveillance, 2021, 7, e24199.	1.2	7
64	Gender equity in interstitial lung disease. Lancet Respiratory Medicine,the, 2020, 8, 842-843.	5.2	6
65	Pleuroparenchymal Fibroelastosis after Liver Transplantation. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 222-223.	2.5	6
66	Costs of Workplace Productivity Loss in Patients with Connective Tissue Diseaseâ€“associated Interstitial Lung Disease. Annals of the American Thoracic Society, 2020, 17, 1077-1084.	1.5	5
67	Description of a Multi-faceted COVID-19 Pandemic Physician Workforce Plan at a Multi-site Academic Health System. Journal of General Internal Medicine, 2021, 36, 1310-1318.	1.3	5
68	Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease. Respiratory Research, 2021, 22, 202.	1.4	5
69	Impact of Concomitant Medication Burden on Tolerability of Disease-targeted Therapy and Survival in Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 962-970.	1.5	5
70	Association of BMI with pulmonary function, functional capacity, symptoms, and quality of life in ILD. Respiratory Medicine, 2022, 195, 106792.	1.3	5
71	Oxygen Prescription in Interstitial Lung Disease: 2.5 Billion Years in the Making. Annals of the American Thoracic Society, 2017, 14, 1755-1756.	1.5	4
72	Treatment Initiation in Patients with Interstitial Lung Disease in Canada. Annals of the American Thoracic Society, 2021, 18, 1661-1668.	1.5	4

#	Article	IF	Citations
73	Malignancy Risk Associated With Mycophenolate Mofetil or Azathioprine in Patients With Fibrotic Interstitial Lung Disease. Chest, 2022, 161, 1594-1597.	0.4	4
74	Clinical relevance of rheumatoid factor and antiâ€citrullinated peptides in fibrotic interstitial lung disease. Respirology, 0, , .	1.3	4
75	Environmental and occupational exposures in interstitial lung disease. Current Opinion in Pulmonary Medicine, 2022, 28, 414-420.	1.2	4
76	Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 941-942.	2.5	3
77	Long-term monitoring of patients with fibrotic interstitial lung disease: A Canadian Thoracic Society Position Statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 147-155.	0.2	3
78	Occupational exposures and IPF: when the dust unsettles. Thorax, 2020, 75, 828-829.	2.7	3
79	Management of Fibrotic Hypersensitivity Pneumonitis. Clinics in Chest Medicine, 2021, 42, 311-319.	0.8	3
80	Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respiratory Medicine, 2022, 191, 106722.	1.3	3
81	Optimizing care for patients with interstitial lung disease during the COVID-19 pandemic. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2020, 4, 226-228.	0.2	2
82	From the 10,000-foot View, We Need Ground-Level Data on Air Pollution and Idiopathic Pulmonary Fibrosis. Chest, 2020, 158, 446-448.	0.4	2
83	Looking Ahead. Clinics in Chest Medicine, 2021, 42, 375-384.	0.8	2
84	Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. European Respiratory Journal, 2021, 57, 2004219.	3.1	2
85	Prescribing Patterns and Tolerability of Mycophenolate and Azathioprine in Patients with Nonidiopathic Pulmonary Fibrosis Fibrotic Interstitial Lung Disease. Annals of the American Thoracic Society, 2022, 19, 863-867.	1.5	2
86	Perceptions of Genetic Testing: A Mixed-Methods Study of Patients with Pulmonary Fibrosis and Their First-Degree Relatives. Annals of the American Thoracic Society, 2022, 19, 1305-1312.	1.5	2
87	Impact of processing technique on bronchoalveolar lavage cellular analysis. European Respiratory Journal, 2018, 51, 1701769.	3.1	1
88	Transbronchial lung cryobiopsy in ILD: the data we've been waiting for. Lancet Respiratory Medicine,the, 2020, 8, 129-130.	5.2	1
89	Mycophenolate mofetil and azathioprine in chronic hypersensitivity pneumonitis. , 2016, , .		1
90	The Long-Term Respiratory Perils of War. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	1

#	Article	IF	Citations
91	Hot tub lung: A tale of two manifestations. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 67-70.	0.2	0
92	Transbronchial lung cryobiopsy for ILD: Ready or not, here it comes?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 257-258.	0.2	0
93	Response. Chest, 2018, 154, 727-728.	0.4	0
94	That's a WRAP: laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis. Lancet Respiratory Medicine,the, 2018, 6, 655-657.	5.2	0
95	Contralateral recurrence of inflammatory myofibroblastic tumour of the lung 10 years after pneumonectomy. Thorax, 2018, 73, 1089-1090.	2.7	0
96	Update in the diagnostic approach to fibrotic interstitial lung disease. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 155-159.	0.2	0
97	Clinical characterization of patients with interstitial lung disease: Report from a single Canadian Center. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 310-315.	0.2	0
98	Reply: BAL lymphocyte percentage is as good as the company it keeps. European Respiratory Journal, 2021, 57, 2100092.	3.1	0
99	Antacid Therapy in Idiopathic Pulmonary Fibrosis. Chest, 2021, 159, 475-476.	0.4	0
100	Birds of a Feather Precipitate Together. Archivos De Bronconeumologia, 2021, , .	0.4	0
101	Progress and Innovation in Interstitial Lung Disease. Clinics in Chest Medicine, 2021, 42, xiii-xiv.	0.8	0
102	Reply to: Pleuroparenchymal Fibroelastosis Induced by Liver Transplantation?. American Journal of Respiratory and Critical Care Medicine, 2021, , .	2.5	0